While ffERG b-wave amplitudes appeared maximally restored during June through August 2022 (Figure 2), high levels of TRPM1 autoantibodies remained detectable in the patient’s serum during this same period (Figures 3, 4), confirming that circulating TRPM1 autoantibodies alone are not sufficient to cause visual impairment (19). The gene discussed is TRPM1; the disease is Visual impairment.